Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.

Like Comment

Subcutaneous recombinant interferon-beta1a (IFN-1a SC) is indicated for treatment of relapsing multiple sclerosis (RMS); however, it is associated with development of flu-like syndrome (FLS) in 75% of patients. No recommendations are available on whether evening or morning administration could induce better or worse FLS.Primary objective was to investigate whether morning administration of IFN-1a 44g (Rebif) would affect the severity of FLS versus evening administration, in patients with RMS. Secondary objectives were to investigate whether timing of administration could lead to a better quality of life.Multicenter, open-label, 12-week, randomized, controlled, parallel-group, phase 4 study.Of 217 patients screened at 29 Italian sites, 200 were included in the study. Among these, 104 patients were randomized to IFN-1a SC administration in the morning and 96 in the evening. Morning administration resulted in higher FLS scores, as measured by the Multiple Sclerosis Treatment Concern Questionnaire, at week 4 (p=0.0083) and week8 (p=0.0079); however, the difference was no longer significant at the end of 12weeks.IFN-1a evening injections in the first 8weeks of treatment led to an improvement in FLS; when continuing therapy, time of administration could be decided according to patient's lifestyle and preference.



Click here to read the full article @ Journal of neurology
Go to the profile of ClinOwl

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2212 Contributions
1 Followers
0 Following

No comments yet.